

**Timing of antibiotics, volume, and vasoactive infusions in children with sepsis admitted to intensive care.**

**ESM\_1\_Joffe:**

**The case report form and study manual used for the chart review.**

---

**Authors:** Bregje M van Paridon BSc<sup>1</sup>, Cathy Sheppard RN<sup>2</sup>, Gonzalo Garcia Guerra MSc MD<sup>3</sup>, Ari R Joffe MD<sup>3</sup>, for the Alberta Sepsis Network.

**Affiliations:** 1. Erasmus University Medical Center, Rotterdam, the Netherlands; 2. Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada; 3. Department of Pediatrics, Division of Pediatric Critical Care Medicine, University of Alberta, Edmonton, Alberta, Canada

**Corresponding author:** Ari R Joffe MD; 4-546 Edmonton Clinic Health Academy; 11405 87 Ave; Edmonton, Alberta, Canada, T6G 1C9. Email:

[ari.joffe@albertahealthservices.ca](mailto:ari.joffe@albertahealthservices.ca) Phone: 780 2485435. Fax: 888 7901283



**ASN SEPSIS AND TIME OF ANTIBIOTICS AND FLUID BOLUS STUDY: GLOSSARY**

| <b><u>Site of infection</u></b>         | <b><u>Acceptable empiric antibiotic</u></b>   |
|---|---|
| <b>Meningitis (community acquired)</b>  | Cefotaxime,<br>Ceftriaxone,<br>Meropenem,<br>Ceftazidime<br><b>&lt;1month:</b> also accept- Ampicillin and Gentamicin. If <b>proven Listeria</b> [growth from CSF], then only need Ampicillin alone.  |
| <b>Pneumonia<br/>-community</b>         | > 3mos: Ampicillin<br>Any age: any of below<br>Cefuroxime<br>Cefotaxime<br>Ceftriaxone<br>Piperacillin-tazobactam<br>Meropenem<br>Imepenem<br>Levofloxacin<br>If <b>proven MRSA</b> [from blood culture, endotracheal aspirate, or empyema fluid]:<br>Vancomycin<br>Linezolid |
| <b>-nosocomial</b>                      | Piperacillin-tazobactam<br>Meropenem<br>Imepenem<br>Ciprofloxacin<br>If <b>proven MRSA</b> [from blood culture, endotracheal aspirate, or empyema fluid]:<br>Vancomycin<br>Linezolid  |
| <b>Empyema</b>                          | Same as for community acquired pneumonia  |
| <b>Bacteremia<br/>-GPC clumps: CONS</b> | Vancomycin  |
| <b>-GPC clumps:<br/>S.aureus</b>        | Vancomycin<br>Cloxacillin<br>Piperacillin-tazobactam<br>Meropenem<br>Imepenem<br>Cefotaxime   |

|  |   |
|--|---|
|  | <p>Ceftriaxone<br/>Clindamycin<br/>If <u>proven MRSA</u>:<br/>Vancomycin<br/>Linezolid</p>  |
| <p>-GPC chains:<br/>Streptococcus sp.<br/>Enterococcus sp.</p>                             | <p>Vancomycin<br/>Piperacillin-tazobactam<br/>Piperacillin<br/>Meropenem<br/>Imipenem<br/>Ampicillin<br/>Penicillin</p>   |
| <p>-GNB<br/>E coli, Klebsiella sp,<br/>Pseudomonas sp,<br/>Enterobacter sp,<br/>others</p> | <p>Piperacillin-tazobactam<br/>Gentamicin<br/>Tobramycin<br/>Meropenem<br/>Imipenem<br/>Ciprofloxacin<br/>Aztreonam</p>   |
| <p>-Candida sp.</p>  | <p>Amphotericin: B, lipid complex, Abelcet, Ambisome<br/>Echinocandin: caspofungin, micafungin<br/>Fluconazole</p>  |
| <p>Abdominal: appendicitis,<br/>bowel perforation or<br/>surgery, abscess, trauma</p>      | <p>Ampicillin and Gentamicin/Tobramycin<br/>Clindamycin and Gentamicin/Tobramycin<br/>Ciprofloxacin and Metronidazole<br/>Piperacillin-tazobactam<br/>Meropenem<br/>Imipenem<br/>Ertapenem<br/>Ceftriaxone/Cefotaxime and Metronidazole</p>   |
| <p>UTI</p>   | <p>Ampicillin (community acquired)<br/>Gentamicin<br/>Tobramycin<br/>Piperacillin<br/>Piperacillin-tazobactam<br/>Meropenem<br/>Imipenem<br/>TMP/SMX (if sensitive)<br/>Ceftriaxone<br/>Cefotaxime<br/>If <u>proven Enterococci</u> [on urine culture]:<br/>Not to count: gentamicin, tobramycin, TMP/SMX,<br/>Ceftriaxone, or Cefotaxime</p> |
| <p>Fasciitis</p>   | <p>Penicillin and Cefotaxime/Gentamicin/Tobramycin</p>  |

Clindamycin and Cefotaxime/Gentamicin/Tobramycin  
Piperacillin-tazobactam  
Meropenem  
Imepenem  
If proven Group A Streptococcus [Group A  
Streptococcus, or Streptococcus pyogenes on blood  
culture or surgical specimen from fascitis]:  
Penicillin  
Clindamycin  
If proven MRSA [from same specimens as above]:  
Vancomycin  
Linezolid

**Mediastinitis**

One of Vancomycin/Cloxacillin/Ancef  
AND/OR:  
Piperacillin/tazobactam  
Gentamicin  
Tobramycin  
Imepenem  
Meropenem  
Ciprofloxacin

**Miscellaneous less common sites:**

**a. Mastoiditis**

same as for meningitis  
Piperacillin/tazobactam  
Imipenem

**b. Cellulitis**

same as for fascitis

**c. Bacterial Tracheitis**

same as for pneumonia (except for ampicillin)

**d. Burns**

same as for mediastinitis (i.e. nosocomial flora)

**e. Retropharyngeal  
abscess**

same as for pneumonia

**f. Unknown source  
(community acquired)**

same as for meningitis

**Definitions:**

**Fluid bolus:**

-NS, RL, Plasmalyte, 5% albumin, PRBC, FFP, Platelets  
-20ml/kg

**Time of presentation:**

-ER: admission time to ER.  
-ward or PICU: time that the following have occurred- new fever >38.2 and blood culture sent.

**Antibiotic time:**

-fulfills the criteria: intravenously (can be enterally for: ciprofloxacin, metronidazole, TMP/SMX), appropriate choice for site  
-time: at the start of the infusion; if two antibiotics are required, then at the start time of the infusion for the second antibiotic.

**Septic shock:**

-inotropes (dopamine, dobutamine, epinephrine, norepinephrine, phenylephrine, or milrinone) started on day 1 of ASN.

**Sepsis:**

-as in ASN: SIRS due to confirmed or suspected infection

**Nosocomial infection:**

-the infection develops more than 72 hours after hospital admission

**Community acquired infection:**

-the infection is present on admission to hospital, or incubating on admission to hospital [defined as the infection developing within 72 hours of hospital admission].